These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31718458)

  • 1. Group sequential design for historical control trials using error spending functions.
    Wu J; Li Y
    J Biopharm Stat; 2020 Mar; 30(2):351-363. PubMed ID: 31718458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An additive boundary for group sequential designs with connection to conditional error.
    Xi D; Gallo P
    Stat Med; 2019 Oct; 38(23):4656-4669. PubMed ID: 31338847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group sequential designs using a family of type I error probability spending functions.
    Hwang IK; Shih WJ; De Cani JS
    Stat Med; 1990 Dec; 9(12):1439-45. PubMed ID: 2281231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On adaptive error spending approach for group sequential trials with random information levels.
    Liu Q; Lim P; Nuamah I; Li Y
    J Biopharm Stat; 2012; 22(4):687-99. PubMed ID: 22651109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian sequential design using alpha spending function to control type I error.
    Zhu H; Yu Q
    Stat Methods Med Res; 2017 Oct; 26(5):2184-2196. PubMed ID: 26187736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implementing type I & type II error spending for two-sided group sequential designs.
    Rudser KD; Emerson SS
    Contemp Clin Trials; 2008 May; 29(3):351-8. PubMed ID: 17933592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
    Wu J; Zhu L; Li Y
    J Biopharm Stat; 2023 Dec; ():1-14. PubMed ID: 38146192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the spending function method and the Christmas tree correction for group sequential trials.
    Stallard N; Facey KM
    J Biopharm Stat; 1996 Jul; 6(3):361-73. PubMed ID: 8854238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exact critical values for group sequential designs with small sample sizes.
    Rom DM; McTague JA
    J Biopharm Stat; 2020 Jul; 30(4):752-764. PubMed ID: 32151177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leveraging historical data into oncology development programs: Two case studies of phase 2 Bayesian augmented control trial designs.
    Smith CL; Thomas Z; Enas N; Thorn K; Lahn M; Benhadji K; Cleverly A
    Pharm Stat; 2020 May; 19(3):276-290. PubMed ID: 31903699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computations for group sequential boundaries using the Lan-DeMets spending function method.
    Reboussin DM; DeMets DL; Kim KM; Lan KK
    Control Clin Trials; 2000 Jun; 21(3):190-207. PubMed ID: 10822118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gatekeeping procedure to test a primary and a secondary endpoint in a group sequential design with multiple interim looks.
    Tamhane AC; Gou J; Jennison C; Mehta CR; Curto T
    Biometrics; 2018 Mar; 74(1):40-48. PubMed ID: 28589692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CP function: an alpha spending function based on conditional power.
    Jiang Z; Wang L; Li C; Xia J; Wang W
    Stat Med; 2014 Nov; 33(26):4501-14. PubMed ID: 25100033
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of randomized controlled confirmatory trials using historical control data to augment sample size for concurrent controls.
    Yuan J; Liu J; Zhu R; Lu Y; Palm U
    J Biopharm Stat; 2019; 29(3):558-573. PubMed ID: 30612514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Group sequential Holm and Hochberg procedures.
    Tamhane AC; Xi D; Gou J
    Stat Med; 2021 Oct; 40(24):5333-5350. PubMed ID: 34636081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample size calculation based on efficient unconditional tests for clinical trials with historical controls.
    Shan G; Moonie S; Shen J
    J Biopharm Stat; 2016; 26(2):240-9. PubMed ID: 25551261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a historical control group in a noninferiority trial assessing a new antibacterial treatment: A case study and discussion of practical implementation aspects.
    Dejardin D; Delmar P; Warne C; Patel K; van Rosmalen J; Lesaffre E
    Pharm Stat; 2018 Mar; 17(2):169-181. PubMed ID: 29282862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beta spending function based on conditional power in group sequential design.
    Ni S; Zhong Z; Jiang Z; Zhao Y; Wu J; Yu H; Bai J
    Biom J; 2024 Apr; 66(3):e2300094. PubMed ID: 38581099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Familywise error for multiple time-to-event endpoints in a group sequential design.
    Thomsen HF; Lausvig NL; Pipper CB; Andersen S; Damgaard LH; Emerson SS; Ravn H
    Stat Med; 2024 Aug; 43(18):3417-3431. PubMed ID: 38852994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.